Article

You have full text access to this OnlineOpen article

pH-dependent stability of neuroserpin is mediated by histidines 119 and 138; Implications for the control of β-sheet A and polymerization

  1. Didier Belorgey1,*,
  2. Peter Hägglöf1,
  3. Maki Onda2,
  4. David A. Lomas1

Article first published online: 1 DEC 2009

DOI: 10.1002/pro.299

Issue

Protein Science

Protein Science

Volume 19, Issue 2, pages 220–228, February 2010

Additional Information

How to Cite

Belorgey, D., Hägglöf, P., Onda, M. and Lomas, D. A. (2010), pH-dependent stability of neuroserpin is mediated by histidines 119 and 138; Implications for the control of β-sheet A and polymerization. Protein Science, 19: 220–228. doi: 10.1002/pro.299

Author Information

  1. 1

    Department of Medicine, University of Cambridge, Cambridge Institute for Medical Research, Cambridge CB2 0XY, United Kingdom

  2. 2

    Department of Biological Science, Osaka Prefecture University, Nakaku, Sakai, Osaka 599-8570, Japan

*Department of Medicine, University of Cambridge, Cambridge Institute For Medical Research, Cambridge CB2 0XY, UK

Publication History

  1. Issue published online: 21 JAN 2010
  2. Article first published online: 1 DEC 2009
  3. Accepted manuscript online: 1 DEC 2009 12:00AM EST
  4. Manuscript Accepted: 16 NOV 2009
  5. Manuscript Revised: 24 SEP 2009
  6. Manuscript Received: 14 JUL 2009

Funded by

  • Medical Research Council (UK)
  • the Engineering and Physical Sciences Research Council (UK)
  • Papworth NHS Trust (UK)
  • Swedish Society for Medical Research (Sweden)
  • Wenner-Gren Foundation (Sweden)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (781K)

References

  • 1
    Silverman GA, Bird PI, Carrell RW, Coughlin PB, Gettins PG, Irving JI, Lomas DA, Luke CJ, Moyer RW, Pemberton PA, Remold-O'Donnell E, Salvesen GS, Travis J, Whisstock JC ( 2001) The serpins are an expanding superfamily of structurally similar but functionally diverse proteins: evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 276: 33293–33296.
  • 2
    Galliciotti G, Sonderegger P ( 2006) Neuroserpin. Front Biosci 11: 33–45.
  • 3
    Miranda E, Lomas DA ( 2006) Neuroserpin: a serpin to think about. Cell Mol Life Sci 63: 709–722.
  • 4
    Huntington JA ( 2006) Shape-shifting serpins—advantages of a mobile mechanism. Trends Biochem Sci 31: 427–435.
  • 5
    Hastings GA, Coleman TA, Haudenschild CC, Stefansson S, Smith EP, Barthlow R, Cherry S, Sandkvist M, Lawrence DA ( 1997) Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurons. Implications for the regulation of motor learning and neuronal survival. J Biol Chem 272: 33062–33067.
  • 6
    Krueger SR, Ghisu GP, Cinelli P, Gschwend TP, Osterwalder T, Wolfer DP, Sonderegger P ( 1997) Expression of neuroserpin, an inhibitor of tissue plasminogen activator, in the developing and adult nervous system of the mouse. J Neurosci 17: 8984–8996.
  • 7
    Belorgey D, Crowther DC, Mahadeva R, Lomas DA ( 2002) Mutant neuroserpin (S49P) that causes familial encephalopathy with neuroserpin inclusion bodies is a poor proteinase inhibitor and readily forms polymers in vitro. J Biol Chem 277: 17367–17373.
  • 8
    Berger P, Kozlov SV, Cinelli P, Kruger SR, Vogt L, Sonderegger P ( 1999) Neuronal depolarization enhances the transcription of the neuronal serine protease inhibitor neuroserpin. Mol Cell Neurosci 14: 455–467.
  • 9
    Yepes M, Lawrence DA ( 2004) New functions for an old enzyme: nonhemostatic roles for tissue-type plasminogen activator in the central nervous system. Exp Biol Med 229: 1097–1104.
  • 10
    Docagne F, Nicole O, Marti HH, MacKenzie ET, Buisson A, Vivien D ( 1999) Transforming growth factor-ß1 as a regulator of the serpins/t-PA axis in cerebral ischemia. FASEB J 13: 1315–1324.
  • 11
    Yepes M, Sandkvist M, Wong MK, Coleman TA, Smith E, Cohan SL, Lawrence DA ( 2000) Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood 96: 569–576.
  • 12
    Cinelli P, Madani R, Tsuzuki N, Vallet P, Arras M, Zhao CN, Osterwalder T, Rulicke T, Sonderegger P ( 2001) Neuroserpin, a neuroprotective factor in focal ischemic stroke. Mol Cell Neurosci 18: 443–457.
  • 13
    Yepes M, Sandkvist M, Coleman TA, Moore E, Wu JY, Mitola D, Bugge TH, Lawrence DA ( 2002) Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent. J Clin Invest 109: 1571–1578.
  • 14
    Lebeurrier N, Liot G, Pascual Lopez-Atalaya J, Orset C, Fernandez-Monreal M, Sonderegger P, Ali C, Vivien D ( 2005) The brain-specific tissue-type plasminogen activator inhibitor, neuroserpin, protects neurons against excitotoxicity both in vitro and in vivo. Mol Cell Neurosci 30: 552–558.
  • 15
    Kinghorn KJ, Crowther DC, Sharp LK, Nerelius C, Davis RL, Chang HT, Green C, Gubb DC, Johansson J, Lomas DA ( 2006) Neuroserpin binds Aβ and is a neuroprotective component of amyloid plaques in Alzheimer disease. J Biol Chem 281: 29268–29277.
  • 16
    Fabbro S, Seeds NW ( 2009) Plasminogen activator activity is inhibited while neuroserpin is upregulated in the Alzheimer disease brain. J Neurochem 109: 303–315.
    Direct Link:
  • 17
    Davis RL, Shrimpton AE, Holohan PD, Bradshaw C, Feiglin D, Collins GH, Sonderegger P, Kinter J, Becker LM, Lacbawan F, Krasnewich D, Muenke M, Lawrence DA, Yerby MS, Shaw CM, Gooptu B, Elliott PR, Finch JT, Carrell RW, Lomas DA ( 1999) Familial dementia caused by polymerization of mutant neuroserpin. Nature 401: 376–379.
  • 18
    Davis RL, Shrimpton AE, Carrell RW, Lomas DA, Gerhard L, Baumann B, Lawrence DA, Yepes M, Kim TS, Ghetti B, Piccardo P, Takao M, Lacbawan F, Muenke M, Sifers RN, Bradshaw CB, Kent PF, Collins GH, Larocca D, Holohan PD ( 2002) Association between conformational mutations in neuroserpin and onset and severity of dementia (erratum 2002, 360, 1102). Lancet 359: 2242–2247.
  • 19
    Miranda E, Römisch K, Lomas DA ( 2004) Mutants of neuroserpin that cause dementia accumulate as polymers within the endoplasmic reticulum. J Biol Chem 279: 28283–28291.
  • 20
    Miranda E, MacLeod I, Davies MJ, Perez J, Römisch K, Crowther DC, Lomas DA ( 2008) The intracellular accumulation of polymeric neuroserpin explains the severity of the dementia FENIB. Hum Mol Genet 17: 1527–1539.
  • 21
    Takasawa A, Kato I, Takasawa K, Ishii Y, Yoshida T, Shehata MH, Kawaguchi H, Mohafez OM, Sasahara M, Hiraga K ( 2008) Mutation-, aging-, and gene dosage-dependent accumulation of neuroserpin (G392E) in endoplasmic reticula and lysosomes of neurons in transgenic mice. J Biol Chem 283: 35606–35613.
  • 22
    Belorgey D, Sharp LK, Crowther DC, Onda M, Johansson J, Lomas DA ( 2004) Neuroserpin Portland (Ser52Arg) is trapped as an inactive intermediate that rapidly forms polymers: implications for the epilepsy seen in the dementia FENIB. Eur J Biochem 271: 3360–3367.
    Direct Link:
  • 23
    Yamasaki M, Li W, Johnson DJ, Huntington JA ( 2008) Crystal structure of a stable dimer reveals the molecular basis of serpin polymerization. Nature 455: 1255–1258.
  • 24
    Davis RL, Holohan PD, Shrimpton AE, Tatum AH, Daucher J, Collins GH, Todd R, Bradshaw C, Kent P, Feiglin D, Rosenbaum A, Yerby MS, Shaw CM, Lacbawan F, Lawrence DA ( 1999) Familial encephalopathy with neuroserpin inclusion bodies. Am J Pathol 155: 1901–1913.
  • 25
    Gourfinkel-An I, Duyckaerts C, Camuzat A, Meyrignac C, Sonderegger P, Baulac M, Brice A ( 2007) Clinical and neuropathologic study of a French family with a mutation in the neuroserpin gene. Neurology 69: 79–83.
  • 26
    Coutelier M, Andries S, Ghariani S, Dan B, Duyckaerts C, van Rijckevorsel K, Raftopoulos C, Deconinck N, Sonderegger P, Scaravilli F, Vikkula M, Godfraind C ( 2008) Neuroserpin mutation causes electrical status epilepticus of slow-wave sleep. Neurology 71: 64–66.
  • 27
    Onda M, Belorgey D, Sharp LK, Lomas DA ( 2005) Latent S49P neuroserpin forms polymers in the dementia familial encephalopathy with neuroserpin inclusion bodies. J Biol Chem 280: 13735–13741.
  • 28
    Lomas DA, Mahadeva R ( 2002) α1-antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy. J Clin Invest 110: 1585–1590.
  • 29
    Belorgey D, Hägglöf P, Karlsson-Li S, Lomas DA ( 2007) Protein misfolding and the serpinopathies. Prion 1: 15–20.
  • 30
    Dafforn TR, Mahadeva R, Elliott PR, Sivasothy P, Lomas DA ( 1999) A kinetic mechanism for the polymerization of α1-antitrypsin. J Biol Chem 274: 9548–9555.
  • 31
    Zhou A, Faint R, Charlton P, Dafforn TR, Carrell RW, Lomas DA ( 2001) Polymerization of plasminogen activator inhibitor-1. J Biol Chem 276: 9115–9122.
  • 32
    Zhou A, Stein PE, Huntington JA, Carrell RW ( 2003) Serpin polymerization is prevented by a hydrogen bond network that is centered on His-334 and stabilized by glycerol. J Biol Chem 278: 15116–15122.
  • 33
    Stanley P, Serpell LC, Stein PE ( 2006) Polymerization of human angiotensinogen: insights into its structural mechanism and functional significance. Biochem J 400: 169–178.
  • 34
    Hill RM, Parmar PK, Coates LC, Mezey E, Pearson JF, Birch NP ( 2000) Neuroserpin is expressed in the pituitary and adrenal glands and induces the extension of neurite-like processes in AtT-20 cells. Biochem J 345: 595–601.
  • 35
    Parmar PK, Coates LC, Pearson JF, Hill RM, Birch NP ( 2002) Neuroserpin regulates neurite outgrowth in nerve growth factor-treated PC12 cells. J Neurochem 82: 1406–1415.
    Direct Link:
  • 36
    Ishigami S, Sandkvist M, Tsui F, Moore E, Coleman TA, Lawrence DA ( 2007) Identification of a novel targeting sequence for regulated secretion in the serine protease inhibitor neuroserpin. Biochem J 402: 25–34.
  • 37
    Takehara S, Onda M, Zhang J, Nishiyama M, Yang X, Mikami B, Lomas DA ( 2009) The 2.1-Å crystal structure of native neuroserpin reveals unique structural elements that contribute to conformational instability. J Mol Biol 388: 11–20.
  • 38
    Devlin GL, Chow MK, Howlett GJ, Bottomley SP ( 2002) Acid denaturation of α1-antitrypsin: characterization of a novel mechanism of serpin polymerization. J Mol Biol 324: 859–870.
  • 39
    Boudier C, Bousquet J-A, Schauinger S, Michels B, Bieth JG ( 2007) Reversible inactivation of serpins at acidic pH. Arch Biochem Biophys 466: 155–163.
  • 40
    Elliott PR, Pei XY, Dafforn TR, Lomas DA ( 2000) Topography of a 2.0Å structure of α1-antitrypsin reveals targets for rational drug design to prevent conformational disease. Protein Sci 9: 1274–1281.
    Direct Link:
  • 41
    Johnson DJ, Langdown J, Li W, Luis SA, Baglin TP, Huntington JA ( 2006) Crystal structure of monomeric native antithrombin reveals a novel reactive center loop conformation. J Biol Chem 281: 35478–35486.
  • 42
    Ricagno S, Caccia S, Sorrentino G, Antonini G, Bolognesi M ( 2009) Human neuroserpin: structure and time-dependent inhibition. J Mol Biol 388: 109–121.
  • 43
    Zhou A, Huntington JA, Pannu NS, Carrell RW, Read RJ ( 2003) How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol 10: 541–544.
  • 44
    Zhang Q, Buckle AM, Law RH, Pearce MC, Cabrita LD, Lloyd GJ, Irving JA, Smith AI, Ruzyla K, Rossjohn J, Bottomley SP, Whisstock JC ( 2007) The N terminus of the serpin, tengpin, functions to trap the metastable native state. EMBO Rep 8: 658–663.
  • 45
    Barker-Carlson K, Lawrence DA, Schwartz BS ( 2002) Acyl-enzyme complexes between tissue-type plasminogen activator and neuroserpin are short-lived in vitro. J Biol Chem 277: 46852–46857.
  • 46
    Makarova A, Mikhailenko I, Bugge TH, List K, Lawrence DA, Strickland DK ( 2003) The low density lipoprotein receptor-related protein modulates protease activity in the brain by mediating the cellular internalization of both neuroserpin and neuroserpin-tissue-type plasminogen activator complexes. J Biol Chem 278: 50250–50258.
  • 47
    Renatus M, Engh RA, Stubbs MT, Huber R, Fischer S, Kohnert U, Bode W ( 1997) Lysine 156 promotes the anomalous proenzyme activity of tPA: X-ray crystal structure of single-chain human tPA. EMBO J 16: 4797–4805.
View Full Article (HTML) Get PDF (781K)